New Age Alpha Advisors LLC Grows Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

New Age Alpha Advisors LLC raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 59,271.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,312 shares of the biopharmaceutical company’s stock after buying an additional 8,298 shares during the period. New Age Alpha Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $5,921,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of the company. FSA Wealth Management LLC purchased a new stake in Regeneron Pharmaceuticals in the third quarter worth $26,000. OFI Invest Asset Management purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter worth about $28,000. Rakuten Securities Inc. raised its stake in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 15 shares during the period. Avalon Trust Co purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at about $36,000. Finally, Crowley Wealth Management Inc. bought a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $36,000. Institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on REGN. Piper Sandler dropped their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research note on Monday, January 27th. Robert W. Baird dropped their target price on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 5th. BMO Capital Markets reduced their price target on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a research report on Tuesday, February 4th. Citigroup dropped their price objective on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Finally, Leerink Partners raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $762.00 to $834.00 in a report on Wednesday, February 5th. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $637.36 on Friday. The firm has a fifty day simple moving average of $683.88 and a two-hundred day simple moving average of $800.34. Regeneron Pharmaceuticals, Inc. has a twelve month low of $629.02 and a twelve month high of $1,211.20. The company has a market capitalization of $69.68 billion, a PE ratio of 16.65, a P/E/G ratio of 2.34 and a beta of 0.27. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the business posted $11.86 EPS. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.55%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.